InvestorsHub Logo
Followers 156
Posts 6363
Boards Moderated 1
Alias Born 08/06/2004

Re: bb8675309 post# 303762

Thursday, 03/18/2021 9:50:08 AM

Thursday, March 18, 2021 9:50:08 AM

Post# of 461544
This is stupid BS, first they have to recruit 1,600 AD patients, I guess the analyst is overlooking that fact, he is going to look stupid later THIS year. Recruiting that many AD patients will take at least a year, look how long it has taken AVXL to recruit 450 AD patients using many sites in several countries.

"Cassava plans to start the first of its two late-stage studies of simufilam in the third quarter of this year. That study will evaluate the disease-modifying effects of the drug in treating Alzheimer's. The biotech expects to kick off the second pivotal study -- to evaluate symptomatic improvement in patients who receive simufilam -- in the fourth quarter."

https://finance.yahoo.com/m/511f4e3d-5fb7-3d08-b34e-ed7038020c6c/why-cassava-sciences-stock-is.html

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News